The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
暂无分享,去创建一个
M. Borad | J. Adams | J. Berenson | Malka A Frantzen | E. Roussos | R. Vescio | N. Sjak-Shie | C. Altamirano | Hank H. Yang | J. Friedman | Zhi-qun Wu | K. Parker | Steven J. Manyak | A. Mikail | J. Neeser | Mark H Ma
[1] Beverly S Mitchell,et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Berenson,et al. Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma , 2002 .
[3] L. Moscinski,et al. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. , 2001, Cancer research.
[4] L. Liu,et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. , 2001, Cancer research.
[5] P. Vaagenes,et al. [Steroid treatment of shock lung--tune for re-evaluation?]. , 2001, Tidsskrift for Den Norske Laegeforening.
[6] P. Elliott,et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.
[7] P. Elliott,et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.
[8] R. Kyle,et al. Update on the treatment of multiple myeloma. , 2001, The oncologist.
[9] S. Alkan,et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. , 2000, Human pathology.
[10] J. Puzas,et al. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. , 2000, Cancer research.
[11] Korey R. Johnson,et al. Nuclear Factor-κB/IκB Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells , 2000 .
[12] S-G Hwang,et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.
[13] S. Han,et al. NF-κB Activation Is Related to the Resistance of Lung Cancer Cells to TNF-α-Induced Apoptosis , 2000 .
[14] P. Elliott,et al. Proteasome Inhibition: a New Strategy in Cancer Treatment , 2000, Investigational New Drugs.
[15] P. Elliott,et al. Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.
[16] B. Rayet,et al. Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.
[17] T. Gilmore,et al. Control of apoptosis by Rel/NF-κB transcription factors , 1999, Oncogene.
[18] G. Haegeman,et al. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. , 1999, Molecular pharmacology.
[19] H. Kantarjian,et al. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Seminars in hematology.
[20] F. Vittimberga,et al. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. , 1999, Surgery.
[21] R. Hay,et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.
[22] B. Barlogie,et al. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.
[23] J. Cusack,et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.
[24] R. Weichselbaum,et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.
[25] R. Bell,et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Ghosh,et al. Signal transduction through NF-κB , 1998 .
[27] R. Weichselbaum,et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. , 1997, Cancer research.
[28] A. Rubagotti,et al. A Randomized Trial of Chemotherapy with or without Estrogenic Recruitment in Locally Advanced Breast Cancer , 1997, Tumori.
[29] A. Israël,et al. IκB proteins: structure, function and regulation , 1997 .
[30] David Baltimore,et al. NF-κB: Ten Years After , 1996, Cell.
[31] D. White,et al. Rel/NF-kappaB/IkappaB proteins and cancer. , 1996, Oncogene.
[32] M A Wainberg,et al. Regulation of Human Immunodeficiency Virus Type 1 and Cytokine Gene Expression in Myeloid Cells by Nf-b/rel Transcription Factors , 2022 .
[33] R. Hay,et al. Regulation of the DNA binding activity of NF-κB , 1995 .
[34] L. Rosen,et al. Multiple myeloma and chronic lymphocytic leukemia , 1995, Current opinion in hematology.
[35] M. Rocchi,et al. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. , 1994, Blood.
[36] Tom Maniatis,et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.
[37] S. Goodbourn,et al. Proteolytic degradation of MAD3 (IϰBα) and enhanced processing of the NF-ϰB precursor p105 are obligatory steps in the activation of NF-ϰB , 1993 .
[38] A. Baldwin,et al. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. , 1993, Genes & development.
[39] Y. Ben-Neriah,et al. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB , 1993, Nature.
[40] G. Franzoso,et al. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] W. Schaffner,et al. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.
[42] J. Tobias,et al. Management of multiple myeloma. , 1987, British journal of hospital medicine.
[43] S. Masters,et al. 14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.
[44] T. Hamblin,et al. Management of multiple myeloma today. , 1999, Seminars in hematology.
[45] K. Arastéh,et al. Malignant gastrointestinal lymphomas in patients with AIDS. , 1997, Digestion.
[46] R. Alexanian,et al. Management of multiple myeloma. , 1995, Seminars in hematology.
[47] Mutual regulation of the transcriptional activator NF-cB and its inhibitor, I1cB-a , 2022 .